Prosecution Insights
Last updated: April 19, 2026

Examiner: GREENE, IVAN A

Tech Center 3700 • Art Units: 1619 1638 1654 3786

This examiner grants 18% of resolved cases

Performance Statistics

18.5%
Allow Rate
-51.5% vs TC avg
654
Total Applications
+6.6%
Interview Lift
1736
Avg Prosecution Days
Based on 590 resolved cases, 2023–2026

Rejection Statute Breakdown

0.2%
§101 Eligibility
8.5%
§102 Novelty
46.6%
§103 Obviousness
24.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17939524 COMPOSITE HYDROGEL FOR LIGHT-CURED 3D CELL-LADEN PRINTING AND PREPARATION METHOD AND APPLICATION THEREOF Non-Final OA SHANDONG UNIVERSITY
18540458 Synthesis of Thiophene Derivatized Polyphenolic Calixarenes Non-Final OA University of Cincinnati
18543657 COMPOSITIONS CONTAINING ACTIVE AGENT AND UV PROTECTION PROPERTIES Non-Final OA L'OREAL
16763629 COMPOSITION COMPRISING A UV-SCREENING AGENT, AN ACRYLIC COPOLYMER AND AN ACRYLAMIDOMETHYLPROPANESULFONIC ACID COPOLYMER Final Rejection L'OREAL
17879926 THERAPEUTIC PATCH FOR GASTROINTESTINAL TRACT AND METHOD OF MANUFACTURING SAME Final Rejection INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
18933195 FORMULATIONS AND DOSES OF PEGYLATED URICASE Final Rejection Cartesian Therapeutics, Inc.
18914964 METHOD AND COMPOSITION FOR RESTORING HOMEOSTASIS, TREATING, AND PREVENTING DEGENERATIVE DISEASES, ACHIEVING ANTI-AGING EFFECT Non-Final OA Vector Vitale IP LLC
16722249 METHOD OF TREATING NONALCOHOLIC STEATOHEPATITIS Final Rejection Vector Vitale IP LLC
17759592 Droplet Formation and Particle Morphology Final Rejection Elektrofi, Inc.
18284886 AGENTS FOR DYEING KERATINOUS MATERIAL, IN PARTICULAR HUMAN HAIR, CONTAINING AMINOSILICONES, PIGMENTS AND PARTICULAR ALKYLENE GLYCOLS Non-Final OA HENKEL AG & CO. KGAA
17507951 BACTERICIDAL COATING COMPOSITIONS AND METHODS USING SAME Non-Final OA Rowan University
18704300 PHOTOCURABLE COMPOSITION Non-Final OA THREEBOND CO., LTD.
18506664 METHOD OF FORMING PEPTIDE-COATED NANOPARTICLES Non-Final OA Icahn School of Medicine at Mount Sinai
18479393 DUAL RESPONSIVE BRAIN TARGETED NANOPARTICLES FOR USE IN TREATMENT OF ALZHEIMER'S DISEASE Final Rejection UNIVERSITY OF SOUTH CAROLINA
18706770 COSMETIC Non-Final OA SHISEIDO COMPANY, LTD.
17720625 PHARMACEUTICAL COMPOSITIONS COMPRISING GRANULATED BEMPEDOIC ACID Final Rejection Esperion Therapeutics, Inc.
18564588 MRNA DELIVERY USING LIPID NANOPARTICLES Non-Final OA THE UNIVERSITY OF BRITISH COLUMBIA
18161857 METHODS FOR PREPARING PARTICLES AND RELATED COMPOSITIONS Final Rejection ModernaTX, INC.
18170602 COMPOSITION FOR SUSTAINED-RELEASE INJECTION COMPRISING DESLORELIN Final Rejection INVENTAGE LAB INC.
18556818 Pharmaceutical Composition For Treating Hyperlipidemia And Preparation Method Therefor Non-Final OA SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.
18553986 IN VIVO ORAL INSULIN DELIVERY VIA COVALENT ORGANIC FRAMEWORKS Non-Final OA New York University in Abu Dhabi Corporation
18548702 METHODS AND SYSTEMS FOR MAKING POLYMER MICROSPHERES Non-Final OA Oakwood Laboratories, LLC
18054356 Procedure for the purification of biodegradable thermoplastic polymeric particles for medical and/or pharmaceutical use Final Rejection LABORATORIOS FARMACEUTICOS ROVI, S.A.
17935022 NANOPARTICLE PHARMACEUTICAL COMPOSITIONS WITH REDUCED NANOPARTICLE SIZE AND IMPROVED POLYDISPERSITY INDEX Final Rejection Sirnaomics, Inc.
18223944 OCULAR COMPOSITIONS Non-Final OA Re-Vana Therapeutics Ltd.
18005114 Polypeptide Polymer-Doped Bone Marrow Cavity Filler and Use Thereof in Treatment of Osteomyelitis Non-Final OA SHANGHAI FIRST PEOPLE'S HOSPITAL
17920317 Transfection and Transduction System Final Rejection N4 Pharma UK Limited
17915251 CANCER THERAPY WITH MICROBUBBLES Final Rejection SONOTARG LIMITED
17913978 WHOLE-CELL CONSTITUENT TRANSPORT SYSTEM AND APPLICATION THEREOF Final Rejection SUZHOU ERSHENG BIOPHARMACEUTICAL CO., LTD.
17783022 GOLDEN LIPID NANOPARTICLES FOR GENE THERAPY Final Rejection UNIVERSIDAD DEL PAÍS VASCO/EUSKAL HERRIKO UNIBERTSITATEA

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month